Navigation Links
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
Date:10/24/2008

Seeks Approval for Use in Epilepsy as Adjunctive Treatment in Partial Onset

Seizures

RARITAN, N.J., Oct. 24 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for carisbamate, a new investigational compound for the adjunctive treatment of partial onset seizures in patients 16 years of age and older.

The filing is supported by data from three placebo-controlled clinical trials in patients with epilepsy. Results from the first study were presented at the Ninth EILAT Conference on Antiepileptic Drugs in June and results from two additional studies will be presented at the annual meeting of the American Epilepsy Society later this year.

In 1999, J&JPRD and SK Holdings Co., Ltd. (SK) entered into a license agreement to develop and commercialize carisbamate. J&JPRD received global marketing rights for the compound. If approved by the FDA, carisbamate will be marketed by Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Carisbamate has received provisional approval by the FDA to be marketed under the brand name of COMFYDE(TM).

About Partial Onset Seizures and Epilepsy

Epilepsy is one of the most common disorders of the nervous system, defined by recurrent unprovoked seizures. It is categorized as "primary generalized" or "partial onset" depending on the specific location of the abnormal electrical activity in the brain that typically characterizes the disorder. Partial-onset seizures are the most common type, and are generally more difficult to treat. Virtually any movement, sensory, or emotional symptom can occur as part of a partial seizure, including complex visual or auditory hallucinations. There are two categories of partial onset seizures: simple partial seizures (in which consciousness is retained), and complex parti
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
2. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
5. Johnson & Johnson Announces Changes to Accelerate Growth
6. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
7. Two-time Defending NASCAR Sprint Cup Series Champion Jimmie Johnson Joins the Team at CORD:USE Cord Blood Bank to Help Win the Race for Life
8. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
9. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
10. Craig Johnson Joins Ardea Biosciences Board of Directors
11. Migenix averts proxy contest; reaches agreement with DJohnson holdings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... ... The global aptamers market is expected to reach $244.93 ... 17.89% between 2015 and 2020. The aptamer type segments included in this report ... is segmented into diagnostics, therapeutics development, R&D, and other applications. Diagnostics applications will ...
(Date:7/7/2015)... DE (PRWEB) , ... July 07, 2015 , ... ... that work together to lower barriers to innovation in life science R&D, has ... in the last quarter include another top ten pharmaceutical company joining as a ...
(Date:7/6/2015)... , July 6, 2015  Approximately 1% of the ... into their chromosomes. These individuals are three times more ... published in one of the nation,s leading medical journals ... in Canada.  Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... 6 (HHV-6) causes roseola (also known as "sixth disease") ...
(Date:7/6/2015)... 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused ... Viveve,s Chief Executive Officer, and Scott Durbin , Viveve,s ... 9, 2015. , , , DATE:    , ... , TIME:     , , , 12:15 PM EDT ... http://tinyurl.com/viveve   ,    ...
Breaking Biology Technology:Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5Pistoia Alliance Continues to Attract New Members 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3
... But when information is transmitted down fiber optic cables, ... be decoded at the other end. Two factors are ... otherwise known as the wavelength, and the orientation of ... EPFL and the Swiss Federal Laboratories for Materials Science ...
... Rodney Landreneau and Matthew Schuchert from the University of Pittsburgh ... the 2011 Society of Surgical Oncology (SSO) conference in San ... at UPMC Shady Side Hospital as well as the Head ... of the Division of Cardiothoracic Surgery at UPMC St. Margaret ...
... Texas, April 12, 2011 Wound Management Technologies, Inc., ... care solutions, today announced that the Company has signed ... Texas to distribute CellerateRX® gel products in select states ... agreement calls for 1st year sales of at least ...
Cached Biology Technology:Better lasers for optical communications 2Precision Therapeutics' ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer 2WNDM Signs $1.5 M Multiyear Regional Distribution Agreement 2WNDM Signs $1.5 M Multiyear Regional Distribution Agreement 3
(Date:6/10/2015)... , June 10, 2015 ... Sensor Market by Technology (Ultrasound, TOF, Structured Light, ... Electronics, Entertainment, Automotive) and by Geography - Trends ... MarketsandMarkets, the market is expected to reach $3,319.71 ... 25.51% between 2015 and 2020. Browse ...
(Date:6/9/2015)... 09, 2015 Research and Markets  ( ... "Gesture Recognition & Touchless Sensing Market by ... & Others), Product (Biometric & Sanitary Equipment) & ... report to their offering. The total ... to reach $ 23.55 Billion by 2020 at ...
(Date:6/8/2015)... 8, 2015  The Secure Identity & ... of Troy Potter of L-3 National ... is a non-profit association that was established in ... and implementation of solutions that protect and secure ... Photo ...
Breaking Biology News(10 mins):3D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5
... Spain, show for the first time that bacteria, in ... of the sparkling wine known as Cava. They report ... the American Society for Microbiology. , "Bacteria found in ... wine quality in terms of aroma, flavor, bubble size ...
... new protein that plays a critical role in enabling the ... stress, as well as in the progressive loss of heart ... findings, they said, suggest new approaches to prevent or reverse ... the U.S. The team reports its findings in the August ...
... leishmaniasis, which is the most severe form of that group ... year. It is caused by a protozoan, Leishmania infantum, transmitted ... disease, which can rapidly lead to death if no treatment ... population is hit heavily by infection. It acts as parasite ...
Cached Biology News:After the yeast is gone bacteria continue to develop flavor of sparkling wine 2Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 3Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 4
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: